SCIENTIFIC REPORTS

OPEN

Identification of candidate genes for congenital heart defects on proximal chromosome 8p

Tingting Li^{1,*}, Chunjie Liu^{1,*}, Yuejuan Xu², Qianqian Guo¹, Sun Chen¹, Kun Sun¹ & Rang Xu²

Received: 05 May 2016

Accepted: 10 October 2016

Published: 03 November 2016

With the application of advanced molecular cytogenetic techniques, the number of patients identified as having abnormal chromosome 8p has increased progressively. Individuals with terminal 8p deletion have been extensively described in previous studies. The manifestations usually include cardiac anomalies, developmental delay/mental retardation, craniofacial abnormalities, and multiple other minor anomalies. However, some patients with proximal deletion also presented with similar phenotypic features. Here we describe a female child with an 18.5-Mb deletion at 8p11.23–p22 that include the cardiac-associated loci *NKX2-6* and *NRG1*. Further mutation screening of these two candidate genes in 143 atrial septal defect patients, two heterozygous mutations *NKX2-6* (c.1A > T) and *NRG1* (c.1652G > A) were identified. The mutations were described for the first time in patients with congenital heart disease (CHD). The c.1A > T *NKX2-6* generated a protein truncated by 45 amino acids with a decreased level of mRNA expression, whereas the *NRG1* mutation had no significant effect on protein functions. Our findings suggest that 8p21–8p12 may be another critical region for 8p-associated CHD, and some cardiac malformations might be due to *NKX2-6* haploinsufficiency. This study also links the *NKX2-6* mutation to ASD for the first time, providing novel insight into the molecular underpinning of this common form of CHD.

Congenital heart disease (CHD) is the most common developmental defect. The prevalence of CHD at birth is estimated to be between 75 and 90 per 10000 live births¹, and it is caused predominantly by genetic factors, including single-gene mutations and chromosomal aberrations. At present, the genetic mechanism underlying CHD is incompletely understood, and much attention is paid to the association between the disease and certain chromosomal aberrations. For example, the majority of individuals with trisomy 18 (Edwards syndrome) have ventricular septal defects (VSD) and patent ductus arteriosus (PDA)². 22q11 deletions are a relatively common cause of CHD, such as interrupted aortic arch type B and tetralogy of Fallot (TOF) with absent pulmonary valve³. Abnormal dosage of one or more genes within these aberrant chromosomal fragments occurs frequently and at a higher frequency in CHD patients, and these genes are often also associated with extracardiac abnormalities.

Deletion of a segment of the short arm of chromosome 8, which is prone to rearrangements due to nonallelic homologous recombination⁴, has been described numerous times, and distal deletions of 8p are associated with CHD⁵. The CHD spectrum includes, but is not limited to, pulmonary stenosis⁶, secundum ASD, tetralogy of Fallot⁷, complete atrioventricular canal, double outlet right ventricle⁸. In addition to CHD, extracardiac manifestations usually present as low birth weight, growth deficiency, mental retardation, dolichocephaly, ears that are low-set and malformed, high-arched palate, thin lips and micrognathia⁹. The critical region associated with CHD, specifically ASD, is 8p23.1¹⁰. However, individuals carrying more proximal deletions have also been reported to have CHD and similar associated extracardiac characteristics, suggesting that critical loci for heart defects exist more proximally as well.

A cluster of genes affecting cardiac differentiation is located on the distal 8p region¹¹. Haploinsufficiency of *GATA4*, the cardiac transcription factor gene that maps to this locus, is considered to be the primary cause of CHD in patients with monosomy of distal 8p^{4,7}. Additional studies also suggest that *SOX7* haploinsufficiency may exacerbate the cardiac phenotype of individuals with *GATA4* deletions⁸, and deletion of *GATA4* alone or in conjunction with *NEIL2* may result in cardiac defects in humans¹². Nevertheless, it is interesting to note that some

¹Department of Pediatric Cardiology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, P.R. China. ²Scientific Research Center, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, P.R. China. *These authors contributed equally to this work. Correspondence and requests for materials should be addressed to R.X. (email: rangxu@shsmu.edu.cn)

Figure 1. Proband at age 11 months. (A) Frontal view of face. (B) lateral view. (C) The high arched palate is clearly visible. (D) Toe deformity. (E,F) The simian line. (G,H) Echocardiogram showing secundum ASD; MRI of the brain showing periventricular leukomalacia.

individuals without above genes on the deleted 8p also present with a wide spectrum of CHD. These observations caused us to wonder whether haploinsufficiency of any other genes in this interval may contribute to the heart defects observed in individuals with 8p deletion.

With this in mind, we present the case of a female child with an 18.5-Mb interstitial deletion of proximal 8p and a syndrome that include cardiac anomaly, developmental delay/mental retardation, and craniofacial abnormalities. By comparing our case and previously reported CHD cases with partially overlapping deletions, coupled with DNA sequence analysis and cytobiology experiments, we delineated another critical region of proximal 8p and identified candidate pathogenic genes for the CHD component of the comprehensive phenotype.

Results

Proband description. The proband is the first and only child of healthy, nonconsanguineous parents, who were both 25 years old at the time of her birth. Birth weight was 2800 g (<middle weight -1SD) and height was 49 cm; head circumference was not available. Delivery was by caesarean section after full-term gestation. The pregnancy and delivery were uneventful. At the age of 3 months the child was diagnosed with ostium secundum ASD, which was later surgically corrected. MRI of the brain at 9 months showed periventricular leukomalacia. At 11 months, weight was 4600 g (<middle weight -3SD); height was 62 cm (<average height -3SD); head circumference was 39.1 cm (<average head circumference -3SD). She could neither raise her head nor sit up, and physical examination revealed severe developmental delay and intellectual disability (Fig. 1). At 15 months, weight was 6800 g (<middle weight -3SD); height was 65.8 cm (<average height -3SD); head circumference was 41.2 cm (<average head circumference -3SD) and bone-strength test showed calcium deficiency. She was not able to walk or talk. Detailed clinical features of the patient are shown in Table 1.

Molecular and cytogenetic analysis. G-banding of the proband's chromosomes demonstrated a significant deletion of chromosome 8p and a paracentric inversion of chromosome 13q in all metaphases analyzed (Fig. 2A). To verify loss of genomic material from chromosome 8p, we further performed CytoScan HD array analysis and identified an 18.5-Mb region loss of genomic copy numbers at 8p22–p11.23, refining the karyotype to 46,XX,der(8)inv(13), arr 8p22–p11.23(18,634,986–37,160,315)x1 (Fig. 2B,C). Eighty-two genes documented in the OMIM database were located within the deleted region on chromosome 8p. The chromosome karyotype of the mother was normal and that of the father was 46,XY,22ps+, suggesting that the deletion of the proband was *de novo*.

	P1	P 2	P 3	P 4	P 5	P6	P7	Present
Reference	42	43	9	6	6	44	45	—
Gender	M	M	F	M	M	M	M	F
Deletion 8p	p21.lp23.1	p11.23p21.1	p11.23p21.3	p21p23	p21p23	p12p21.3	p22p12	p11.23p22
DD/MR	+	+	+	+	+	+	+	+
Microcephaly	+	—	+	+	+	+	—	+
Neuropathy	NA	+	NA	NA	NA	—	NA	+
Cerebral MRI abnormality	NA	—	NA	NA	NA	+	NA	+
Hypertelorism	—	+	+	—	+	NA	NA	+
Epicanthal folds	+	+	+	+	+	+	NA	+
Short nose	—	NA	+	NA	NA	NA	NA	+
Malformed ears	+	+	+	+	+	+	+	—
Micrognathia	+	+	+	NA	NA	NA	NA	—
Small mouth	+	+	+	+	—	NA	NA	—
Thin lips	NA	+	+	NA	NA	+	NA	+
Upslant palpebral fissures	—	—	—	NA	NA	+	NA	+
High arched palate	+	—	+	—	—	NA	NA	+
Heart Defects	CAVC, PS	ASD, PDA, MI	PS	AVC, PS, D, PLSVC, HRV	AVC, SAS, PLSVC	VSD	VSD, PDA, PA	ASD
Genitourinary anomalies	+	+	—	+	+	+	NA	—
Ocular abnormality	NA	+	NA	NA	NA	+	NA	+
Auditory problems	NA	NA	NA	NA	NA	+	NA	—
cleft palate	NA	+	—	NA	NA	NA	NA	—
Simian creases	NA	NA	—	NA	NA	NA	NA	+
Spheryocytosis	NA	+	—	NA	NA	—	NA	—
malformed hands, feet	+	+	+	NA	NA	NA	NA	+
others	1	2	3	—	—	NA	4	—

Table 1. Clinical features of the proband and previously reported CHD patients with partially overlapping chromosome 8p deletions. (since 1995) DD/MR: developmental delay/mental retardation; ASD: atrial septal defect; PDA: patent ductus arteriosus; MI: mitral insufficiency; PS: pulmonary stenosis; VSD: ventricle septum defect; CAVC: complete atrioventricular canal; AVC: atrioventricular canal; SAS: subaortic stenosis; PLSVC: persistent left superior vena cava; HRV: hypoplastic right ventricle; D: dextrocardia; NA: not assessable. Others: 1. cryptorchidism and hypospadias; 2. bilateral undescended testis, 11 pairs of ribs; 3. bilateral inguinal hernias, anal atresia; 4. hypospadias, hirschprung disease.

Mutation screening. Genes within the 18.5-M interval with reported expression in cardiac tissues or with roles in heart development, including *NKX2-6* (NM_001136271) and *NRG1* (NM_013956), were considered CHD candidates. To determine whether disruption of *NKX2-6* or *NRG1* could explain the CHD phenotype, we screened all coding exons and flanking introns in these genes in 143 sporadic ASD patients and 200 normal Chinese children. As a result, we identified two nonsynonymous mutations that result in amino acid changes in two unrelated ASD patients.

A heterozygous sequence variation of *NKX2-6* was detected in 1/143 ASD patients, with a mutational prevalence of 0.6999% (Fig. 3A). This mutation site was not found in 200 normal Chinese children. Specifically, the *NKX2-6* missense mutation (c.1A > T) was not located in the highly conserved DNA-binding homeodomain but disrupted the start codon of the gene (ATG to TTG). The mutation is not described in the dbSNP, HGMD, or 1000 GP database, and it has not been previously reported in the literature in association with any disease. The affected residue is highly conserved across vertebrates (Fig. 3B).

Sequence analysis of *NRG1* identified a heterozygous mutation in 1/143 ASD patients with the same mutational prevalence as *NKX2-6*. The mutation consisted of a change from guanine to adenine at nucleotide position 1652 (c.1652G > A), corresponding to conversion of a basic arginine to a polar neutral glutamine at amino acid position 551 (p.R551Q), in the cytoplasmic tail domain (Fig. 3A). Mutation R551Q had been reported to the dbSNP database with ID rs141355195 and a frequency of 0.1% in the 1000 Genomes Project phase 1 population. The affected residue was evolutionarily well conserved in *NRG1* orthologs in other species (Fig. 3B).

Impact of *NKX2-6* mutation on mRNA and protein expression. To understand the effects of c.1A > T on *NKX2-6* mRNA and protein levels, we constructed C-terminal FLAG-tagged *NKX2-6* wild-type and c.1A > T mutant expression vector. COS7 cells were transfected with the *NKX2-6* wild-type or mutant vector, or pcDNA3.1 vector as a control. We first compared the levels of mRNA in cultured cells by quantitative PCR (qPCR). *NKX2-6* mRNA level in c.1A > T cells was dramatically reduced to ≈33% of the level in wild-type cell lines (Fig. 4A).

C.1A > T is a missense mutation predicted to start the *NKX2-6* translation at the second AUG codon (amino acid M46), suggesting that the truncated protein is p.M1_R45del. M46 is in frame with the canonical start codon. We analysis the proteins by an immunoblotting using anti-Flag antibody as well as anti-*NKX2-6* antibody. The

Figure 2. Results of molecular and cytogenetic analysis. (A) G-banded karyotype showing a karyotype of 46,XX,del(8)(p22p11.23)inv(13). The arrows indicate the breakpoints on normal chromosomes. (B) CytoScan HD array present with an 18.5-Mb deletion at chromosome bands 8p22–p11.23(18,634,986–37,160,315)x1 (NCBI build 37/hg19). (C) zoomed-in view. Red spots indicate the sites of NKX2-6 and NRG1.

Figure 3. Sequence analysis of NKX2-6 and NRG1. (A) Gene sequencing peak map showing the NKX2-6 and NRG1 mutations, the arrow indicates the altered heterozygous nucleotides of c.1A > T in NKX2-6 and c.1652G > A in NRG1. (B) Alignment of multiple NKX2-6 and NRG1 amino acid sequences among species. The NKX2-6 and NRG1 amino acid residues affected by these mutations are evolutionarily conserved across various species.

Figure 4. Expression analysis of NKX2-6 in COS7 cells. (A) NKX2-6 mRNA expression of c.1A > T (Mut) compared with wild-type (WT). mRNA levels normalized to that of GAPDH and then to WT. (B,C) Western blots showing the proteins produced by cells transfected with wild-type, c.1A > T, and c.A1_A135del (Trunc) NKX2-6 vector. Tubulin was used as the loading control for normalization.

Figure 5. Functional analysis of NRG1 in COS7 cells. (A) Intracellular levels of wild-type (WT) and R551Q mutant (Mut) NRG1 proteins. GAPDH was used as the loading control for normalization. (B) Western blot analysis of the release of the extracellular domain in the culture medium. (C) Cellular localization of wild-type and mutants NRG1 was analyzed by immunofluorescence staining.

results showed that the molecular weight of the mutant protein was 5 kDa less than wild-type (30 kDa versus 35 kDa) (Fig. 4B,C). To test the hypothesis that c.1A > T cells produce p.M1_R45del NKX2-6 proteins, we next generated expression constructs encoding a C-terminal FLAG-tagged truncated NKX2-6 beginning at the M46 codon (c.A1_A135del). Overexpression of these proteins in COS7 cells followed by western analysis demonstrated that proteins encoded by c.1A > T mutant showed similar bands to c.A1_A135del NKX2-6 in the SDS-gel, (Fig. 4B,C), which was also further confirmed by mass spectrometer (Supplemental Fig. S1).

Mutation results in no change in NRG-1 protein and subcellular localization. We evaluated the function of the NRG1 p.R551Q mutant protein by overexpressing the wild-type and mutant proteins in COS7 cell. Western analysis of lysates of cells expressing type I NRG1 β 1a using anti-NRG1 α/β 1/2 antibody against the cytoplasmic domain of the protein revealed prominent bands of 60 kDa and 110 kDa. It has been suggested that the 110-kD band represents the NRG1 pro-protein, and the 60-kD band the cleaved NRG1 intracellular fragments¹³. Based on amino acid sequences, the calculated molecular weight of type I NRG1 β 1a is 73 kDa. That the protein bands are larger than predicted is likely due to posttranslational modifications such as glycosylation. In the cultured medium, a 45-kDa FLAG-tagged peptide was observed, representing the N-terminal fragment of type I NRG1 β 1a. However, the R551Q mutation of NRG1 does not seem to grossly alter the protein expression (Fig. 5A) or the release of extracellular domains (Fig. 5B). Cellular localization of wild-type and mutant NRG1 was analyzed by immunofluorescence staining with anti-NRG1 α/β 1/2 antibody. Wild-type and mutant NRG1 localized to the cell membrane and the intracellular organelles (endoplasmic reticulum, Golgi apparatus, etc.) but not the nucleus. No apparent difference in localization patterns was observed between mutant and wild-type (Fig. 5C).

Discussion

Proximal 8p deletions carried by CHD patients often occur in the 8p21–p12 region. Individuals with a cytogenetically detectable 8p deletion display a series of congenital malformations that often includes CHD, congenital diaphragmatic hernia¹⁴, skeletal deformity¹⁵, autism¹⁶, hypospadias and seizures⁶. Of these, CHD has been well described in distal 8p deletion patients in the past years, and the phenotype-karyotype correlations have assigned the critical deletion region for heart defects to band 8p23^{5,6}. However, heart malformations are frequently described in patients with proximal 8p deletion in the literature^{6,9}, which suggests that there is a need to broaden the critical deletion region on chromosome 8p that is associated with CHD. In clinical practice, we encountered a female patient with an aberrant proximal 8p region, who was diagnosed with ASD, delayed development, impaired intelligence, and abnormal facial appearance. Detailed examination using microarray chromosomal testing revealed the precise 18.5-Mb region of the deletion at 8p22–p11.23, which includes 82 OMIM genes. Subsequently, we summarized the clinical, cytogenetic, and molecular analyses of previously reported heart defects patients who carried overlapping deletions (Fig. 6 and Table 1). All of these patients had a similar phenotype including such features as CHD, delayed development, mental retardation, microcephaly, distinct craniofacial abnormalities. Importantly, all deleted 8p fragments in these patients encompassed 8p12, 8p21 or both, leading us to hypothesize that the 8p21–8p12 deletion is the another critical region accounting for CHD.

NKX2-6 is the candidate gene for CHD on 8p21–p12. A particular feature of the comprehensive phenotype may result from haploinsufficiency of one or more genes in the chromosome copy number variation region. NKX2-6 is a member of the NK-2 family of transcription factors¹⁷ that maps to the deleted proximal

Figure 6. Summary overview of clinical characteristics in our patient and previously reported CHD patients with overlapping deletions.

8p region. *NKX2-6* is detected in embryos between embryonic day 8.0 (E8.0) and E11.5, but not in later-stage embryos. In the heart, *NKX2-6* is expressed in mouse embryos from E8.0–8.5 in posterior myocardial progenitors, then in sinus venosus and dorsal pericardium, and from E9.5 in outflow tract myocardium^{18,19}. *NKX2-6* and *NKX2-5* belong to the cardiac *NK-2* family, which are the vertebrate relatives of *drosophila tinman*²⁰. Spatiotemporal expression profiles and functions of *NKX2-6* partially overlap with those of *NKX2-5* during embryogenesis¹⁸, and loss of *NKX2-6* could be compensated for by an increase in *NKX2-5* expression²¹.

Missense or frameshift mutations in *NKX2-6* have been found in different CHDs including persistent truncus arteriosus/common arterial trunk^{19,22}, TFO, DORV, and VSD^{23,24}. However, the functional role of *NKX2-6* is far from clarified because there have been no detailed functional studies of *NKX2-6* mutations. In this paper, a genetic analysis of *NKX2-6* was performed in 135 patients with ASD, and only one missense mutation, c.1A > T, was identified. The *NKX2-6* gene consists of two exons that encode the 301 amino acids of *NKX2-6* and lacks 5' or 3' untranslated regions (UTRs). Subsequent cytobiology experiments of $\approx 33\%$ reduction in *NKX2-6* mRNA levels in c.1A > T cells compared with control cell lines suggests that the mutation at the transcription start site inhibits normal transcription. At the protein level, this mutation causes the loss of the translation start codon ATG for methionine. Further functional studies of the newly identified start codon mutation show that it shifts the initiation start codon to Met+46 (p.M1_R45del), resulting in a protein truncated by 45-amino acids, which contains a conserved transcription repressor tinman domain. Consequently, we propose the N-terminally truncated protein generated by *NKX2-6* mutation may be an etiological factor in heart defects.

***NRG1* might account for the intellectual disability in proximal 8p deleted patients.** *NRG1* belongs to the epidermal growth factor (*EGF*) gene family that is located in chromosomal region 8p12. *NRG1* isoforms differ in their levels and patterns of expression in various tissues, including the brain²⁵, heart²⁶, breast²⁷, and gut²⁸. In the heart, *NRG1* is expressed and released by the endocardial and microvasculature endothelium, and binds to ErbB receptors with its extracellular EGF-like domain, which further activates a large number of signaling cascades, including *Erk 1/2*, *Akt*, and *FAK* in cardiomyocytes^{29–31}. However, no mutations within this gene have been previously identified in CHD, and the R551Q mutation of *NRG1* identified in 143 sporadic ASD patients in this paper, does not alter protein functions. Additionally, extensively studies have shown that *NRG1* and its receptor ErbB4 plays an important role in many aspects of nervous system, including neural development, myelination³², synaptic plasticity³³, radial glia migration³⁴, and neurotransmitter receptor expression³⁵. *NRG1* mutations have been reported to be associated with Alzheimers disease³⁶ and schizophrenia³⁷, and autism³⁸. Therefore, we hypothesis that *NRG1* haploinsufficiency might account for the mental retardation in most of patients with proximal 8p deletion.

Association of the syndromic phenotype with the deletion region. It should be noted that not all patients with proven proximal 8p deletion have cardiac anomalies. There are several possible explanations for this phenomenon. It may reflect the ample phenotypic variability of *NKX2-6* mutations. Compensatory increases in *NKX2-5* may mitigate the effects of *NKX2-6* deletion, as seen in mice homozygous for a targeted mutation of *NKX2-6*. These animals are normal as a result of functional complementation between *NKX2-5* and *NKX2-6*^{18,21}. Alternatively, other genetic modifier loci or stochastic events may also play an important role in determining the phenotype. Moreover, the size of the deletion had no obvious correlation with the severity of heart disease, which may be related to the presence of some other specific phenotypes. Extracardiac symptoms in these patients may be attributable to the neighboring genes within the deletion region. For example, polypeptides neurofilament medium (NEFM) and neurofilament light (NEFL) are subunits of neurofilaments, and NEFM localizes to axons and dendrites³⁹. A mutation in *NEFL* associated with Charcot-Marie-Tooth disease (CMT2E) disrupts both neurofilament assembly and axonal transport of neurofilaments in neurons⁴⁰. Therefore, *NEFM* and *NEFL*, to some extent, might impact the intellectual development in patients with proximal 8p deletion. More studies based on patients with similar phenotypes need to be conducted to test these hypotheses.

Conclusion

In our study, we describe a proximal 8p deletion in a female child and summarize the clinical and molecular cytogenetics findings for this patient, as well as review those for previously reported patients, and conclude that proximal 8p21–8p12 is another critical region for CHD. Mutations identified within *NKX2-6* (p.M1_R45del) and

NRG1 (p. R551Q), the genes for which map to the critical deletion interval, together with a series of functional experiments, expanded our understanding of the significance of the genes in the pathogenesis of CHD. We conclude that CHD associated with proximal 8p deletion is likely due to haploinsufficiency of the cardiac transcription factor NKX2-6. However, in the future, studies employing larger sample sizes, cell-based experiments, and animal models need to be performed to confirm this conclusion.

Materials and Methods

Ethics statement. This study was approved by local ethics committees of Xinhua Hospital and Shanghai Children's Medical Center (SCMC). The written informed consent was obtained from participants or their guardians prior to commencement of investigation, the patients in the study have provided written informed consent to publishing these case details. All methods were performed in accordance with the relevant guidelines and regulations.

Proband and specimens. The proband consulted in the Department of Pediatric Cardiology at the Xinhua Hospital underwent a comprehensive evaluation including individual and familial histories, medical records, cerebrum MRI, intelligence test, oralo, audio, phtharmologic, neurologic, cardiopneumatic, genitourinary examinations. CHD diagnosis was based on 12-lead electrocardiogram, two-dimensional transthoracic echocardiography with color flow Doppler, and confirmed by echocardiography and cardiac catheterizations examinations. A total of 143 ASD sporadic patients and 200 normal Chinese children performed in the study had been recruited in the Department of Pediatric Cardiology at the Xinhua Hospital and Shanghai Children's Medical Center from May 2013 to June 2014. The same procedure was followed for the sporadic samples. Individuals with known chromosomal abnormalities or syndromic cardiovascular defects, such as Down syndrome, DiGeorge syndrome, Alagille syndrome and Holt-Oram syndrome, were excluded from the study. Approximately 1–2 ml of peripheral venous blood sample was collected from every participant after acquiring informed consent.

G-banding chromosome analysis. G-banded chromosome analysis were performed using cultured peripheral blood lymphocytes from the proband and her parents. Two milliliters of peripheral blood samples were collected with heparin added and subjected to RPMI1640 culture medium with 20% calf serum (Invitrogen Gibco, USA) at 37 °C in 5% CO₂. Preparation of metaphase and conventional cytogenetics followed standard cytogenetic protocols. A minimum of 20 metaphases with good chromosome separation were analyzed. Karyotypes were described according to the International System for Human Cytogenetic Nomenclature (International Standing Committee on Human Cytogenetic Nomenclature, 2009).

Affymetrix CytoScan HD array analysis. Genomic DNA of the proband was isolated using the QIAamp DNA Blood Midi Kit (Qiagen) from peripheral blood of the proband following the manufacturer's instructions. The CytoScan HD Array platform (Affymetrix, USA), which is a high-density chip that contains 2.6 million copy number probes with a resolution of 25 kb, was used to detect copy number variations (CNVs) at the DNA level. Duplications and deletions were analyzed using Chromosome Analysis Suite (ChAS) software and the annotations of the genome version GRCH37 (hg19). CNVs that affected a minimum of 50 markers in a 100 kb length were initially considered.

Mutation detection. Polymerase chain reaction amplification was used to screen for DNA variants in the entire coding regions and intron-exon boundaries of *NKX2-6* (NM_001136271) in 143 ASD individuals. The primer sets are as follows: exon 1F 5'-AATGGGGGGCTACGGTCT-3' and exon 1R 5'-CGTTAGGGGTGTGTGAAGC-3'; exon 2aF 5'-CCAGGGAGAGGAAAGTCTTG-3' and exon 2aR 5'-CAGGACGGGCACAGCTACTC-3'; exon 2bF 5'-AGAACCGACGCTACGAAATGC-3' and exon 2bR 5'-GAGATCCCTCCGAAAGAAG-3'²⁴. The referential genomic DNA sequence of *NKX2-6* was derived from GenBank (accession No. NG_030636). Both strands of each PCR product were sequenced with ABI 3730 genetic analyzer (Applied Biosystems).

All isoforms of *NRG1* coding exons and flanking introns were amplified in the same 143 ASD specimens using the FastTarget™ technology (Genesky Biotechnologies Inc, Shanghai, China), which is based on improved multiplex PCR amplification and next-generation sequencing. Sequencing was performed on a Miseq bench-top sequencer (Illumina) with 2 × 300 bps methodology. Paired-end sequencing data from the Miseq reporter software was further analyzed off instrument and used to cross calibration the accuracy of sequences. Furthermore, 12–16 selected high-frequency single nucleotide polymorphisms (SNPs) in the target regions were genotyped to validate the target sequencing results. Candidate variants were confirmed by Sanger sequencing.

The identified *NKX2-6* and *NRG1* sequence variations were queried in the SNP database at NCBI (<http://www.ncbi.nlm.nih.gov/>), the human gene mutation (HGM) database (<http://www.hgmd.org/>) and the 1000 Genome Project (1000 GP) database (<http://www.1000genomes.org/>).

Plasmids and mutagenesis. A full-length human *NKX2-6* cDNA (*NKX2-6* NM_001136271) was inserted into the plasmid 3 × Flag-pcDNA3.1(+) expression vector at the site of HindIII and XhoI. We also generated C-terminally tagged *NKX2-6* expression construct encoding a truncated coding sequence beginning with the M46 codon (c.A1_A145del) by PCR using the following primers: F 5'-GCCCAAGCTTGCCACC ATGGACGCAGAGCCGCGA-3' and R 5'-CCGCTCGAGCCAGGCCCTGACACCCTGCA-3'. The *NRG1* expression vector containing the cDNA of human neuregulin type I-1 isoform (*NRG-1* NM_013956.3) was purchased from Origene (Sino, Biological, China). The *NRG1* cDNA was digested and subcloned into a Flag-pCMV expression vector at the KpnI and XbaI sites. Specific mutations were introduced into *NRG1* and *NKX2-6* cDNAs using the QuikChange XL site-directed mutagenesis kit (Stratagene, La Jolla, California, USA), and the wild-type plasmids were used as the templates. the primers are as follows: *NKX2-6*-F 5'-TTAAGCTTGCCACCTTGCTGCTGAGCCCC-3' and *NKX2-6*-R 5'-GGG

GCTCAGCAGCAAGGTGGCAAGCTTAA-3'; NRG1-F 5'-TGGTTCTTTTGGCCTGCCGGCTATTGGCG-3' and NRG1-R 5'-CGCCAATAGCCGGCAGGCCAAAAGAACCA-3'. Mutant DNAs have been verified by sequencing.

Cell culture and transfection. COS7 cells were maintained in DMEM high glucose medium (HyClone Logan, Utah, USA) containing 10% fetal bovine serum (Invitrogen, California, USA) and 100 U/ml penicillin/streptomycin in humidified air at 37°C with 5% CO₂. 2 µg of the wild-type or mutant constructs were transfected into COS7 cells in 6-well plate. For Western blotting of NRG1, 20 µg of plasmids was transfected into cells in 100 mm dishes. FuGENE HD transfection reagent (Promega, Madison, Wisconsin, USA) was used for transfection according to the manufacturer's protocol.

Antibodies. The primary antibodies used were anti-NKX2-6 (1:1000, Sigma-Aldrich, AB4500670), anti-NRG1 α /β1/2 (C-20) (1:100, Santa Cruz, sc348), anti-FLAG (1:1000, Sigma-Aldrich, F7425), anti-GAPDH (1:10000, Sigma-Aldrich, G9545), anti-tubulin (1:1000, Sigma-Aldrich, T5201). The secondary antibodies used were anti-rabbit (1:10000, Jackson, 111035003), anti-mouse (1:10000, Jackson, 115035003), and Cy3-conjugated affipure goat anti-rabbit IgG (H + L) (1:100, Jackson ImmunoResearch, 111165003).

Western blotting. At 40 hr after transfection, whole cell lysates were made using cell lysis buffer [20 mM Tris pH 7.5, 150 mM NaCl, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM EDTA, 1% Na₃VO₄, 0.5 µg/ml leupeptin, 1 mM phenylmethanesulfonyl fluoride (PMSF)]. For NRG1 conditioned medium, it was collected and filtered through a 0.22 µm pore size sterile filter unit (Millipore) and then concentrated up to 50-fold by centrifugation through a Amicon-10 K (Millipore) concentrator. Protein concentration was determined with Bicinchoninic Acid assay (Beyotime biotechnology, China). 30 µg of total protein was separated on 12% SDS-PAGE gels and transferred to nitrocellulose membranes. Membranes were blocked at room temperature for 1 h, incubated at 4°C overnight with primary antibody, washed and incubated with HRP-conjugated secondary antibodies for 1 h, all in 0.1% Tween/TBS with 5% non-fat dry milk. Detection was performed by ECL western blotting detection reagents according to the manufacturer's instructions.

qRT-PCR. Total RNA was isolated using TRIzol reagent (Life Technologies) according to the manufacturer's instructions. Total RNA (1 µg) was retrotranscribed with PrimeScript™ RT reagent (TaKaRa). qPCR was performed according to the SYBR® Premix Ex Taq™ II protocol (Applied TaKaRa). Expression levels were normalized to the GAPDH house-keeping gene. Primer sequences are as follows: NKX2-6-F 5'-TCCAGAACCGACGCTACAAAT-3' and NKX2-6-R 5'-TAGCAAGAGTAGGGCGACACT-3' (PrimerBank ID:343183349c2); GAPDH-F 5'-ACAACCTTGGTATCGTGGAAGG-3' and GAPDH-R 5'-GCCATCACGCCACAGTTTC-3'.

Mass spectrum analysis. The lysate was separated with 12% SDS-PAGE and the related band was cut for in-gel digestion as described previously⁴¹. The tryptic peptides were analyzed on a nano-HPLC coupled Orbitrap Fusion mass spectrometer (Thermo Fisher Scientific, Waltham, MA). The raw spectra data was processed by protein discovery to extract MS/MS spectra data, which was searched against the Uniprot human database (88,817 sequences) by Mascot (v.2.4, Matrix Science, London, UK). Proteins identification was further filtered by perculator with 1% FDR.

Immunofluorescence and subcellular localization. COS7 cells were seeded onto glass coverslips at 5 × 10⁵ cells/ml. Thirty-six hours after transfection, the cells were washed twice with phosphate buffered saline (PBS), fixed with 4% paraformaldehyde for 20 min at room temperature, washed three times in PBS, permeabilized in 0.1% Triton X/PBS at 4°C for 10 min, and blocked in 1% BSA/0.1% Triton X-100 in PBS at room temperature for 1 h. The cells were incubated with a 1:50 dilution of an anti-NRG1 α /β1/2 (C-20) rabbit polyclonal antibody for 1 h at room temperature, after washing three times in PBS, immunosignals were then detected using the secondary antibody Cy3-conjugated affipure goat anti-rabbit IgG (H + L) at a dilution of 1:100, washed three times in PBS then counterstained with DAPI to detect nuclei. Cells were photographed using an Olympus BX51 fluorescence microscopy.

References

- Kahr, P. C. & Diller, G. P. Almanac 2014: congenital heart disease. *Heart*. **101**, 65–71, doi: 10.5543/tkda (2015).
- Rosa, R. F. *et al.* Trisomy 18: review of the clinical, etiologic, prognostic, and ethical aspects. *Rev. Paul. Pediatr.* **31**, 111–120, doi: 10.1590/S0103-05822013000100018 (2013).
- Lindsay, E. A. & Baldini A. Congenital heart defects and 22q11 deletions: which genes count? *Mol. Med. Today*. **4**, 350–357, doi: 10.1016/S1357-4310(98)01302-1 (1998).
- Shimokawa, O. *et al.* Molecular characterization of del(8)(p23.1p23.1) in a case of congenital diaphragmatic hernia. *Am. J. Med. Genet. A*. **136**, 49–51, doi: 10.1002/ajmg.a.30778 (2005).
- Mei, M. *et al.* Analysis of genomic copy number variations in two unrelated neonates with 8p deletion and duplication associated with congenital heart disease. *Zhonghua. Er. Ke. Za. Zhi*. **52**, 460–463, doi: 10.3760/cma.j.issn.0578-1310.2014.06.013 (2014).
- Digilio, M. C. *et al.* Deletion 8p syndrome. *Am. J. Med. Genet.* **75**, 534–536, doi: 10.1002/(SICI)1096-8628(19980217)75:5 < 534::AID-AJMG15 > 3.0.CO;2-L (1998).
- Pehlivan, T. *et al.* GATA4 Haploinsufficiency in Patients With Interstitial Deletion of Chromosome Region 8p23.1 and Congenital Heart Disease. *Am. J. Med. Genet.* **83**, 201–206, doi: 10.1002/(SICI)1096-8628(19990319)83:3 < 201::AID-AJMG11 > 3.0.CO;2-V (1999).
- Wat, M. J. *et al.* Chromosome 8p23.1 Deletions as a Cause of Complex Congenital Heart Defects and Diaphragmatic Hernia. *Am. J. Med. Genet. A*. **149**, 1661–1677, doi: 10.1002/ajmg.a.32896 (2009).
- Tsukahara, M. *et al.* Interstitial deletion of 8p: report of two patients and review of the literature. *Clin. Genet.* **48**, 41–45, doi: 10.1111/j.1399-0004.1995.tb04052.x (2008).
- Devriendt, K. *et al.* Delineation of the critical deletion region for congenital heart defects, on chromosome 8p23.1. *Am. J. Hum. Genet.* **64**, 1119–1126 (1999).

11. Giglio, S. *et al.* Deletion of a 5-cM region at chromosome 8p23 is associated with a spectrum of congenital heart defect. *Circulation*. **102**, 432–437, doi: 10.1161/01.CIR.102.4.432 (2000).
12. Keittges, E. A. *et al.* Prenatal Diagnosis of Two Fetuses With Deletions of 8p23.1, Critical Region for Congenital Diaphragmatic Hernia and Heart Defects. *Am. J. Med. Genet. A*. **161**, 1755–1758, doi: 10.1002/ajmg.a.35965 (2013).
13. Wang, J. Y., Miller, S. J. & Falls, D. L. The N-terminal Region of Neuregulin Isoforms Determines the Accumulation of Cell Surface and Released Neuregulin Ectodomain. *J. Biol. Chem.* **276**, 2841–2851, doi: 10.1074/jbc.M005700200 (2001).
14. Longoni, M. *et al.* Congenital Diaphragmatic Hernia Interval on Chromosome 8p23.1 Characterized by Genetics and Protein Interaction Networks. *Am. J. Med. Genet. A*. **158**, 3148–3158, doi: 10.1002/ajmg.a.35665 (2012).
15. Pope, K. *et al.* Dextrocardia, Atrial Septal Defect, Severe Developmental Delay, Facial Anomalies, and Supernumerary Ribs in a Child With a Complex Unbalanced 8;22 Translocation Including Partial 8p Duplication. *Am. J. Med. Genet. A*. **158**, 641–647, doi: 10.1002/ajmg.a.34431 (2012).
16. Glancy, M. *et al.* Transmitted duplication of 8p23.1–8p23.2 associated with speech delay, autism and learning difficulties. *Eur. J. Hum. Genet.* **17**, 37–43, doi: 10.1038/ejhg.2008.133 (2008).
17. Biben, C., Hatzistavrou, T. & Harvey, R. P. Expression of NK-2 class homeobox gene Nkx2-6 in foregut endoderm and heart. *Mech. Dev.* **73**, 125–127, doi: 10.1016/S0925-4773(98)00037-9 (1998).
18. Nikolova, M., Chen, X. & Lufkin, T. NKX2-6 expression is transiently and specifically restricted to the branchial region of pharyngeal-stage mouse embryos. *Mech. Dev.* **69**, 215–218 (1997).
19. Ta-Shma, A. *et al.* Conotruncal malformations and absent thymus due to a deleterious NKX2-6 mutation. *J. Med. Genet.* **51**, 268–270, doi: 10.1136/jmedgenet-2013-102100 (2014).
20. Bartlett, H., Veenstra, G. J. & Weeks, D. L. Examining the cardiac NK-2 genes in early heart development. *Pediatr. Cardiol.* **31**, 335–341, doi: 10.1007/s00246-009-9605-0 (2010).
21. Tanaka, M. *et al.* Nkx2.5 and NKX2-6, homologs of Drosophila tinman, are required for development of the pharynx. *Mol. Cell. Biol.* **21**, 4391–4398, doi: 10.1128/MCB.21.13.4391-4398.2001 (2001).
22. Heathcote, K. *et al.* Common arterial trunk associated with a homeodomain mutation of NKX2-6. *Hum. Mol. Genet.* **14**, 585–593, doi: 10.1093/hmg/ddi055 (2005).
23. Wang, J. *et al.* A novel NKX2-6 mutation associated with congenital ventricular septal defect. *Pediatr. Cardiol.* **36**, 646–656, doi: 10.1007/s00246-014-1060-x (2015).
24. Zhao, L. *et al.* Prevalence and spectrum of NKX2-6 mutations in patients with congenital heart disease. *Eur. J. Med. Genet.* **57**, 579–586, doi: 10.1016/j.ejmg.2014.08.005 (2014).
25. Meyer, D. & Birchmeier, C. Multiple essential functions of neuregulin in development. *Nature*. **378**, 386–390, doi: 10.1038/378386a0 (1995).
26. Odiete, O., Hill, M. F. & Sawyer, D. B. Neuregulin in Cardiovascular Development and Disease. *Circ. Res.* **111**, 1376–1385, doi: 10.1161/CIRCRESAHA.112.267286 (2012).
27. Krane, I. M. & Leder, P. NDF/hereregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice. *Oncogene*. **12**, 1781–1788 (1996).
28. Paratore, C. *et al.* Survival and glial fate acquisition of neural crest cells are regulated by an interplay between the transcription factor Sox10 and extrinsic combinatorial signaling. *Development*. **128**, 3949–3961 (2001).
29. Baliga, R. R. *et al.* NRG-1-induced cardiomyocyte hypertrophy. Role of PI-3-kinase, p70(S6K), and MEK-MAPK-RSK. *Am. J. Physiol.* **277**, H2026–H2037 (1999).
30. Timolati, F. *et al.* Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes. *J. Mol. Cell. Cardiol.* **41**, 845–854, doi: 10.1016/j.yjmcc.2006.08.002 (2006).
31. Kuramochi, Y., Guo, X. & Sawyer, D. B. Neuregulin activates erbB2-dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes. *J. Mol. Cell. Cardiol.* **41**, 228–235, doi: 10.1016/j.yjmcc.2006.04.007 (2006).
32. Velanac, V. *et al.* Bace1 processing of NRG1 type III produces a myelin-inducing signal but is not essential for the stimulation of myelination. *Glia*. **60**, 203–217, doi: 10.1002/glia.21255 (2012).
33. Mei, L. & Xiong, W. C. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. *Nat. Rev. Neurosci.* **9**, 437–452, doi: 10.1038/nrn2392 (2008).
34. Poluch, S. & Juliano, S. L. A normal radial glial scaffold is necessary for migration of interneurons during neocortical development. *Glia*. **55**, 822–830, doi: 10.1002/glia.20488 (2007).
35. Corfas, G., Roy, K. & Buxbaum, J. D. Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia. *Nat. Neurosci.* **7**, 575–580, doi: 10.1038/nn1258 (2004).
36. Go, R. C. *et al.* Neuregulin-1 polymorphism in late onset Alzheimer's disease families with psychoses. *Am. J. Med. Genet. B. Neuropsychiatr. Genet.* **139B**, 28–32, doi: 10.1002/ajmg.b.30219 (2005).
37. Walss-Bass, C. *et al.* A novel missense mutation in the transmembrane domain of neuregulin 1 is associated with schizophrenia. *Biol. Psychiatry*. **60**, 548–553, doi: 10.1016/j.biopsych.2006.04.007 (2006).
38. McInnes, L. A. *et al.* The NRG1 exon 11 missense variant is not associated with autism in the Central Valley of Costa Rica. *BMC Psychiatry*. **7**, 21, doi: 10.1186/1471-244X-7-21 (2007).
39. Myers, M. W. *et al.* The human mid-size neurofilament subunit: a repeated protein sequence and the relationship of its gene to the intermediate filament gene family. *EMBO J.* **6**, 1617–1626 (1987).
40. Brownlee, J. *et al.* Charcot-Marie-Tooth disease neurofilament mutations disrupt neurofilament assembly and axonal transport. *Hum. Mol. Genet.* **11**, 2837–2844, doi: 10.1093/hmg/11.23.2837 (2002).
41. Wu Z. *et al.* Quantitative chemical proteomics reveals new potential drug targets in head and neck cancer. *Mol. Cell. Proteomics*. **10**, M111.011635, doi: 10.1074/mcp.M111.011635 (2011).
42. Marino, B. *et al.* Nonrandom Association of Atrioventricular Canal and del(8p) Syndrome. *Am. J. Med. Genet.* **42**, 424–427, doi: 10.1002/ajmg.1320420404 (2005).
43. Okamoto, N. *et al.* Hereditary Spherocytic Anemia With Deletion of the Short Arm of Chromosome 8. *Am. J. Med. Genet.* **58**, 225–229, doi: 10.1002/ajmg.1320580306 (1995).
44. Willemsen, M. H. *et al.* Clinical and molecular characterization of two patients with a 6.75 Mb overlapping deletion in 8p12p21 with two candidate loci for congenital heart defects. *Eur. J. Med. Genet.* **52**, 134–139, doi: 10.1016/j.ejmg.2009.03.003 (2009).
45. Yu, S. *et al.* Genomic profile of copy number variants on the short arm of human chromosome 8. *Eur. J. Hum. Genet.* **18**, 1114–1120, doi: 10.1038/ejhg.2010.66 (2010).

Acknowledgements

We are grateful to the patients and their families for their participation. The project was funded by the grants from the National Natural Science Foundation of China (81270233/H0204), the grant of the Science Committee of Shanghai (13JC1401705), the grant of Shanghai Municipal Commission of Health and Family Planning three-year action plan (GWIV-23). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author Contributions

T.L., Y.X. and R.X. designed the experiments. T.L. and C.L. performed the experiments. T.L. and R.X. analyzed the data and prepared the figures. Q.G., S.C. and K.S. provide the clinical information of the patients. T.L. wrote the main manuscript text. All authors reviewed the manuscript.

Additional Information

Supplementary information accompanies this paper at <http://www.nature.com/srep>

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Li, T. *et al.* Identification of candidate genes for congenital heart defects on proximal chromosome 8p. *Sci. Rep.* **6**, 36133; doi: 10.1038/srep36133 (2016).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

© The Author(s) 2016